source
- Abivax’s ulcerative colitis Phase 3 trial shows promising efficacy but cancer cases raise safety concernsAbivax announced that its Phase 3 maintenance trial in ulcerative colitis produced results it called “landmark,” showing the drug’s ability to keep patients in remission. The company emphasized th…
- Praxis Precision Medicines reports late-stage failure of seizure drug and pauses second trialPraxis Precision Medicines had enjoyed a period of momentum, reporting two notable clinical successes in the past eight months. The company’s pipeline had been viewed positively by investors and an…